Surfing The MASH Tsunami Podcast

Driving The Discussion In Fatty Liver Disease

Drug developers, investors, researchers, and corporate executives…

Every week, a global community of Fatty Liver Disease stakeholders comes together to explore the most important challenges in diagnosing, treating, and developing medications for patients with Fatty Liver Diseases.

Join hepatology researcher and Key Opinion Leader Dr. Stephen Harrison, liver wellness advocate Louise Campbell MSc AP., Forecasting and Pricing guru Roger Green, M.B.A., and their weekly guests as they discuss these issues from their own unique perspectives on the Surfing the NASH Tsunami podcast.

most recent episode ⤵

S5-02.5 - Conversations from the Vault: Jeff McIntyre on ICER Reviews and NITs
SurfingNASH.Com is honored to have the following sponsors

S5 – E02: MASLD Patient Advocates Plan MASH Activities For 2024

Leading MASLD patient advocates Tony Villiotti of NASH kNOWledge, Wayne Eskridge of the Fatty Liver Foundation, Jeff McIntyre of the Global Liver Institute, and Milan Mishkevikj of the European Liver Patients Association join Louise Campbell and Roger Green to share their vision of changes in the MASH world in 2024 along with each organization’s hopes, concerns and plans. The discussion covers the advocates’ hopes and concerns for the year as well as the programs and efforts each considers top priority.

S5 – E01.6 – SurfingMASH Is Back! How Can Consumer Behavior Confound MASH Care?

After a month off in January, SurfingMASH returns for the 2024 calendar year. In this last segment of Episode 1, the co-hosts explore the complexities surrounding advertising and accessibility of metabolic agents in the US market, with a particular focus on how these factors might influence public engagement and healthcare provider education.

This is truly an excellent podcast…(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
This is truly an excellent podcast. Roger Green is joined by Akero Therapeutics' Kitty Yale, Manal Abdelmalek (Duke University), Naim Alkhouri (Arizona Liver Health) and Stephen Harrison from Pinnacle Clinical Research. They go through the FDA's recent webcast and dissect the meaning and directions laid out. Interesting points around histology remaining the surrogate for the evaluation of NASH and how we need to have a better way of quantifying NASH histology
FINALLY!(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
A podcast for the NASH community! So many relevant topics. There are guest speakers almost every week who contribute a new energy to each episode. Keep up the good work coming!
I learn without trying(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
The host and other speakers are engaging to listen to yet not too serious or noting. I find mysweldf learning without trying. Excellent to have this on while working at home or driving while running errands.
At Long Last!(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
We have sorely needed a podcast that allows clinicians and academics to focus own major issues in NASH and NAFLD. Their recent coverage of ILC was timely and incisive. I find myself discussing the episodes with colleagues and Twitter buddies.